# Not losing weight on tirzepatide: what to consider Canonical page: https://bodienvi.com/blog/why-not-losing-weight-tirzepatide Published September 22, 2026. Updated September 22, 2026. By Bodi Envi Clinical Content Team. How much results varied in SURMOUNT-1, what the Zepbound® label says about escalation and dose, what predicts response, and what to raise with a provider. ## A common question with an uncommon amount of variation behind it The headline figures for tirzepatide are large, which makes a slow or flat course feel like a failure. It is worth starting with what the trial actually found about variation, because the averages hide it. This guide reports the spread of results in SURMOUNT-1, what the Zepbound® label says about the timing of escalation and the choice of dose, what a 2026 peer reviewed review says about who responds and when that becomes visible, and the things worth raising with a provider. It does not advise changing a dose, and it does not predict anyone's result. This is general information and not medical advice. SURMOUNT-1 studied Zepbound®, the branded product. Personalized Compounded tirzepatide, which Bodi Envi's programs may include, is not FDA-approved, was not studied in that trial and is not equivalent to the approved product. Your licensed provider is the person to ask about your own course. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ## How much results varied in SURMOUNT-1 SURMOUNT-1, published by Jastreboff and colleagues in the New England Journal of Medicine in 2022, randomized 2,539 adults with obesity or overweight and no diabetes to 5 mg, 10 mg or 15 mg of tirzepatide once weekly or placebo for 72 weeks, including a 20 week escalation period. According to its abstract on PubMed, the mean change in weight at week 72 was 15.0, 19.5 and 20.9 percent across the three doses against 3.1 percent on placebo. The abstract also reports the spread. The proportion of participants who lost at least 5 percent of body weight was 85 percent on 5 mg, 89 percent on 10 mg and 91 percent on 15 mg, against 35 percent on placebo. Turned around, 9 to 15 percent of people on tirzepatide did not lose 5 percent over 72 weeks. And the proportion who lost 20 percent or more was 50 percent on 10 mg and 57 percent on 15 mg, which means roughly half of the people on the higher doses lost less than the round figure that headlines tend to quote. The abstract gives 95 percent confidence intervals for every mean, and the placebo group's 35 percent reaching a 5 percent loss is a reminder that the diet and activity program in the trial produced change on its own for some people and none for others. The trial was also long. Its primary endpoint was measured at 72 weeks, and the first 20 of those were escalation. A person a few months into treatment is being compared, in their own mind, with an endpoint that the trial measured a year and a half in. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ## What the label says about escalation and dose The Zepbound® label describes a starting dose of 2.5 mg once weekly for four weeks, then 5 mg, then increases of 2.5 mg after at least four weeks on the current dose, with 5 mg, 10 mg and 15 mg as the maintenance doses for weight reduction and 15 mg as the maximum. It states that 2.5 mg is for treatment initiation and is not approved as a maintenance dose, and that the escalation exists to reduce the risk of gastrointestinal adverse reactions. On that schedule, reaching 10 mg takes at least 16 weeks and reaching 15 mg at least 24. The label also says to consider treatment response and tolerability when selecting the maintenance dose, and that if a maintenance dose is not tolerated, a lower one should be considered. Response is therefore something the label expects a provider to look at, alongside tolerability, in deciding where a patient's dose settles. It does not say that a slow early course means the dose should rise, and neither does this guide; it says the decision is the provider's and that response is one of its inputs. The label's pharmacokinetics add one more point about timing. Steady-state levels of tirzepatide are reached after about four weeks on a dose, and exposure rises in proportion to the dose, so each step of the schedule takes several weeks to be fully felt. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ## What a review says predicts response A 2026 narrative review by Lopez Delgado and colleagues in Frontiers in Medicine, found through PubMed, looked at why response to obesity medications varies between people. According to its abstract, GLP-1 receptor agonists and dual incretin agonists produce substantial average weight loss in trials, but real-world effectiveness is limited by interindividual variability, gastrointestinal intolerance, incomplete dose escalation, cost and access barriers, poor long-term persistence, and weight plateau or regain in a subset of treated patients. It reports that response heterogeneity reflects interactions among central satiety and reward circuitry, baseline metabolic and glycemic status, sex, baseline adiposity, treatment indication, previous exposure to a GLP-1 medication, adherence and tolerability. The review's most practical finding is about timing. It reports that early on-treatment weight change, usually assessed within 12 to 16 weeks and in some studies of an older medication as early as one month, is the most clinically actionable predictor of longer-term outcomes, and it recommends structured early response monitoring alongside proactive management of adherence and tolerability. Its authors note that genomic tools for predicting response remain investigational. For someone asking why the scale has not moved, that list is the useful part. Several of the factors it names are things a provider can look at directly: whether escalation has been completed or stalled by side effects, whether doses have been missed, and where in the schedule the person actually is. ## Things worth raising with a provider This guide does not diagnose anyone's course. What it can do is turn the sources above into questions for the person who can. Where am I in the schedule? A course measured against the trial's 72 week endpoint while still in the escalation the label describes is being measured against the wrong point. The label's timing is the reference. Has escalation stalled? The review names incomplete dose escalation and gastrointestinal intolerance among the reasons for variation, and the label gives a provider the choice of holding or lowering a dose for tolerability. Whether to stay, hold or move is the provider's decision, informed by both. Have doses been missed? Adherence is on the review's list, and the label's pharmacokinetics mean that missed doses lower the level in the body for weeks. The label's missed dose rule for the branded product, taking a missed dose within four days and otherwise skipping it, is a description, not advice for a compounded prescription; ask your care team what applies to you. Is the dose being measured correctly? Personalized Compounded tirzepatide is typically drawn from a vial with a syringe, and the concentration on the pharmacy label is the only correct conversion. The FDA's statement on unapproved GLP-1 drugs reports dosing errors in both directions with compounded products, and a measuring error is one plain thing to rule out. Do not adjust the dose yourself; the FDA reports adverse events in patients given compounded doses beyond what the label describes. What else has changed? The review's list includes baseline metabolic status and other medications, and the labels ask providers to weigh the whole picture. A new medication, a change in health or a change in activity are all relevant. What does the provider consider a reasonable point to reassess? The review's 12 to 16 week window is the published reference for early response monitoring, and it is a reasonable thing to ask a provider about directly. ## What the care team messaging is for Bodi Envi's programs include ongoing messaging with your care team through the patient portal, and this question is a good use of it: not to ask for a higher dose, but to describe your course, your side effects, any missed doses and how you are measuring, and to ask what the provider makes of it. A licensed provider, through Wasef Health, PC for applicable programs, makes the clinical decisions, and Bodi Envi's pricing does not increase based solely on dosage strength, so whatever the provider decides about your dose has no effect on what you pay. Bodi Envi is a telehealth platform and not a medical practice, pharmacy or medication manufacturer. Personalized Compounded tirzepatide is not FDA-approved and is not equivalent to Zepbound®; the trial and review cited describe the branded product. This is general information and not medical advice, it states no outcome for anyone, and your licensed provider is the person to ask. ## Frequently asked questions ### Did everyone in the tirzepatide trial lose weight? No. In SURMOUNT-1, published in the New England Journal of Medicine in 2022, 85 to 91 percent of participants on the three doses lost at least 5 percent of body weight over 72 weeks, which means 9 to 15 percent did not reach that threshold. The means of 15.0, 19.5 and 20.9 percent are averages of a wide range of individual results. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ### How long does the label's escalation take? The Zepbound® label describes 2.5 mg once weekly for four weeks, then 5 mg, with further increases of 2.5 mg after at least four weeks on each dose, up to maintenance doses of 5 mg, 10 mg or 15 mg. Reaching 15 mg on that schedule takes at least 24 weeks, and the label says 2.5 mg is for initiation and is not approved as a maintenance dose. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ### When did weight change appear in the trial? SURMOUNT-1 measured its primary endpoint at 72 weeks after a 20 week escalation period. A 2026 review in Frontiers in Medicine, found through PubMed, reports that early on-treatment weight change, usually assessed within 12 to 16 weeks, is the most clinically actionable predictor of longer term outcomes. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ### What affects response, according to published sources? The same review lists interindividual variability, gastrointestinal intolerance, incomplete dose escalation, adherence and tolerability, baseline metabolic status, sex and baseline adiposity among the factors associated with response heterogeneity, and notes that weight plateau or regain occurs in a subset of treated patients. ### Should I increase my dose if I am not losing weight? Not on your own. The Zepbound® label says to consider treatment response and tolerability when selecting the maintenance dose, which is the provider's decision, and the FDA has reported adverse events in patients given compounded doses beyond what the label describes. Raise it with your provider. ### Does a compounded product behave the same way as Zepbound®? That has not been shown. SURMOUNT-1 studied Zepbound®. Personalized Compounded tirzepatide is not FDA-approved, is not equivalent to the approved product, and is measured from a vial, so a measuring error is one of the things a provider may want to rule out. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies. ## Sources - Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine, 2022, PubMed: https://pubmed.ncbi.nlm.nih.gov/35658024/ (checked September 2026) - Zepbound® (tirzepatide) injection prescribing information, DailyMed, revised August 2026: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (checked September 2026) - Lopez Delgado et al., Phenotypic and genomic frameworks for precision pharmacotherapy in obesity, a narrative review, Frontiers in Medicine, 2026, PubMed: https://pubmed.ncbi.nlm.nih.gov/42519802/ (checked September 2026) - FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, dated September 1, 2026: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (checked September 2026)